Surreal illustration of origami lungs and myeloma cells dissolving.

Breathless After Treatment? Unveiling the Risks of Bortezomib-Induced Pneumonia

Kai Mendoza in Health & Wellness November 2025 • 3 min read.

"Discover how a common myeloma treatment could be linked to a serious lung condition and what you need to know."

For individuals battling multiple myeloma, treatments like bortezomib offer a beacon of hope. However, like many powerful medications, bortezomib carries potential risks. Recent medical literature highlights a concerning side effect: the development of organizing pneumonia.

Organizing pneumonia is a condition where the lungs' small air sacs (alveoli) and surrounding tissues become inflamed, leading to impaired breathing and other respiratory symptoms. It's crucial for both patients and healthcare providers to recognize the signs of this potential complication to ensure timely intervention and management.

This article explores the connection between bortezomib and organizing pneumonia, offering insights into the symptoms, diagnosis, and management of this condition. Understanding these risks is essential for making informed decisions about treatment and maintaining optimal respiratory health.

The Case: Bortezomib and Lung Complications

Surreal illustration of origami lungs and myeloma cells dissolving.

A recent case report detailed a 72-year-old man who developed organizing pneumonia while undergoing treatment with bortezomib for multiple myeloma. The man, who had a pre-existing condition of interstitial lung disease, received bortezomib alongside dexamethasone. Following the fourth cycle of treatment, he experienced worsened shortness of breath and chest pressure, leading to hospitalization due to hypoxic respiratory failure.

Diagnostic imaging, specifically a chest CT scan, revealed widespread patchy opacification in the lungs, characterized by subsolid density. These areas often presented a nodular or reticular appearance, extending from the apices (top) to the bases (bottom) of the lungs. To confirm the diagnosis, a video-assisted thoracoscopic biopsy was performed, revealing an organizing pneumonia pattern upon pathological examination.

The patient had pre-existing interstitial lung disease, heightening the risk.
Symptoms worsened after the fourth cycle of bortezomib treatment.
Chest CT scans revealed specific patterns indicative of pneumonia.
A biopsy confirmed the organizing pneumonia diagnosis.

The reporting physician stated, "We demonstrate a case of organizing pneumonia secondary to bortezomib."

Protecting Your Lung Health During Myeloma Treatment

While bortezomib is a valuable tool in treating multiple myeloma, this case highlights the importance of vigilance regarding potential lung complications. Patients should promptly report any new or worsening respiratory symptoms, such as shortness of breath, chest pain, or persistent cough, to their healthcare team. Early detection and appropriate management are crucial for minimizing the impact of organizing pneumonia and ensuring the best possible outcomes. Regular monitoring and open communication with your healthcare provider are key to navigating these risks effectively.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What exactly is organizing pneumonia in the context of multiple myeloma treatment?

Organizing pneumonia is a condition affecting the lungs, specifically the alveoli and surrounding tissues. This inflammation leads to impaired breathing and various respiratory symptoms. Recognizing the signs of organizing pneumonia is crucial for timely intervention, especially for individuals undergoing treatments like bortezomib for multiple myeloma.

Can bortezomib, a medication for multiple myeloma, actually cause lung complications like pneumonia?

Yes, it's possible. A recent case report detailed a 72-year-old man who developed organizing pneumonia while being treated with bortezomib for multiple myeloma. He experienced worsened shortness of breath and chest pressure after the fourth cycle of treatment.

What warning signs should I be aware of during myeloma treatment to identify potential lung issues?

Symptoms include new or worsening respiratory issues like shortness of breath, chest pain, or a persistent cough. Promptly reporting these symptoms to your healthcare team is essential for early detection and appropriate management of potential lung complications such as organizing pneumonia.

How is bortezomib-induced organizing pneumonia typically diagnosed?

Diagnostic imaging, such as a chest CT scan, can reveal widespread patchy opacification in the lungs, often characterized by subsolid density with a nodular or reticular appearance. However, a definitive diagnosis typically requires a biopsy, such as a video-assisted thoracoscopic biopsy, to examine the lung tissue for the organizing pneumonia pattern.

If I'm undergoing myeloma treatment with bortezomib, what precautions should I take to protect my lung health, especially if I have a pre-existing lung condition?

Patients undergoing bortezomib treatment, especially those with pre-existing lung conditions like interstitial lung disease, should be closely monitored for respiratory symptoms. Regular communication with your healthcare provider, prompt reporting of any new or worsening symptoms, and appropriate diagnostic measures are crucial for managing the risk of bortezomib-induced organizing pneumonia and ensuring the best possible outcomes. Early detection and intervention can significantly minimize the impact of this complication.